ChartRow logo
Data provided bySource: Twelve Data
SMMT
$10.67-9.73%
as of close, Nov 17, 2026
☾ AH $10.67 -9.73%
PeersBBIOBNTXASNDARGXGHPRAX
Share this page

SMMT — Summit Therapeutics Inc. Common Stock price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in SMMT be worth today? →
SMMT returns: By year · By month · By week · Trailing

Price data

Price
$10.67
YTD price return
-38.99%
YTD total return
-38.99%
Market cap
8.5B
Enterprise value
7.9B
Shares outstanding
799.8M
52W low
$10.53
52W high
$29.23
From 52W high
-63.50%
From 52W low
+1.33%
52W range
1%$10.53–$29.23
Beta
-1.23

Volume

Rel volume
2.19×
30D volume
6M
30D $ vol
90.1M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
none
Insider net 1Y
+$103.6M

Form 4 transactions by trade date, as filed; latest on file 2026-06-12.

Fundamentals

EPS (ttm)
-$1.07
FCF (ttm)
-526.9M
FCF/share
-$0.66
Book value/share
$0.71
ROE
-147.46%
ROA
-120.18%
Current ratio
5.99

Growth (CAGR, ttm) · 10Y

Shares
+7.44%+4.50%+52.27%+30.40%

Per-share growth (CAGR, ttm) · 10Y

Book value/share
+173.58%+70.74%-7.58%n/a
Price
-37.07%+76.80%+14.55%-0.35%
Total return
-37.07%+76.80%+14.55%-0.35%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-10.0×
Fwd P/E
-13.7×
P/B (mrq)
15.1×
FCF yield (ttm)
-6.17%
Buyback yield (realized, 1y)
-7.44%
Shareholder yield (realized, 1y)
-7.44%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
98th
P/B
60th

Bar = where today’s multiple sits in SMMT’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-9.73%
5D
-40.16%
1M
-27.07%
3M
-16.51%
YTD
-38.99%
1Y
-37.05%
5Y
+97.23%
1D
-9.73%
5D
-40.16%
1M
-27.07%
3M
-16.51%
YTD
-38.99%
1Y
-37.05%
5Y
+97.23%

Fundamentals#

Revenue

5Y n/m5Y n/mYoY n/m
— FY25— Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m
— FY25— Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$1.07 TTM−$0.26 Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
−$526.9M TTM−$160.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$525.2M, capex −$1.7M

Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$159.8M, capex −$396K

Shares (diluted)

5Y +975.5%5Y +975.5%YoY +7.4%
779.6M TTM798.2M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$832.7M TTM−$208.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full SMMT financials →

About Summit Therapeutics#

Data provided bySource: Twelve Data

Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.

Miami, FL·265 employees·Biotechnology·smmttx.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding SMMT#

20 of the 193 ETFs ChartRow carries live hold SMMT. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
XBISPDR S&P Biotech ETF1.0%
IBBiShares Biotechnology ETF0.2%
IWPiShares Russell Mid-Cap Growth ETF0.1%
VBRVanguard Small-Cap Value ETF0.0%
VXFVanguard Extended Market ETF0.0%
VHTVanguard Health Care ETF0.0%
ONEQFidelity Nasdaq Composite Index ETF0.0%
VBVanguard Small-Cap ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%